DICERNA PHARMACEUTICALS INC's ticker is DRNA and the CUSIP is 253031108. A total of 1 filers reported holding DICERNA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $5,703,000 | -50.6% | 282,907 | -8.5% | 0.00% | -50.0% |
| Q2 2021 | $11,544,000 | +70.4% | 309,303 | +16.7% | 0.00% | +100.0% |
| Q1 2021 | $6,776,000 | +10.4% | 264,974 | -4.9% | 0.00% | 0.0% |
| Q4 2020 | $6,138,000 | +23.4% | 278,598 | +0.7% | 0.00% | 0.0% |
| Q3 2020 | $4,974,000 | -32.3% | 276,541 | -4.4% | 0.00% | -50.0% |
| Q2 2020 | $7,348,000 | +59.7% | 289,279 | +15.5% | 0.00% | 0.0% |
| Q1 2020 | $4,600,000 | -28.6% | 250,386 | -14.4% | 0.00% | 0.0% |
| Q4 2019 | $6,442,000 | +112.7% | 292,454 | +38.7% | 0.00% | +100.0% |
| Q3 2019 | $3,028,000 | -11.4% | 210,816 | -2.8% | 0.00% | 0.0% |
| Q2 2019 | $3,416,000 | +6.5% | 216,914 | -0.9% | 0.00% | 0.0% |
| Q1 2019 | $3,207,000 | +37.6% | 218,930 | +0.4% | 0.00% | 0.0% |
| Q4 2018 | $2,331,000 | -17.6% | 218,093 | +17.6% | 0.00% | 0.0% |
| Q3 2018 | $2,830,000 | +43.6% | 185,441 | +15.3% | 0.00% | 0.0% |
| Q2 2018 | $1,971,000 | +396.5% | 160,898 | +288.3% | 0.00% | – |
| Q1 2018 | $397,000 | +124.3% | 41,432 | +111.6% | 0.00% | – |
| Q4 2017 | $177,000 | +7.9% | 19,579 | -31.5% | 0.00% | – |
| Q3 2017 | $164,000 | +80.2% | 28,564 | 0.0% | 0.00% | – |
| Q2 2017 | $91,000 | -8.1% | 28,564 | -1.9% | 0.00% | – |
| Q1 2017 | $99,000 | +19.3% | 29,119 | +1.2% | 0.00% | – |
| Q4 2016 | $83,000 | -15.3% | 28,769 | +72.7% | 0.00% | – |
| Q3 2016 | $98,000 | +69.0% | 16,658 | -14.6% | 0.00% | – |
| Q2 2016 | $58,000 | -80.1% | 19,499 | -64.2% | 0.00% | – |
| Q1 2016 | $292,000 | -57.6% | 54,529 | -5.9% | 0.00% | – |
| Q4 2015 | $688,000 | +21.6% | 57,969 | -15.8% | 0.00% | – |
| Q3 2015 | $566,000 | -30.5% | 68,831 | +17.9% | 0.00% | – |
| Q2 2015 | $814,000 | +18.3% | 58,376 | +104.0% | 0.00% | – |
| Q1 2015 | $688,000 | +51.5% | 28,618 | +3.7% | 0.00% | – |
| Q4 2014 | $454,000 | +50.3% | 27,588 | +16.3% | 0.00% | – |
| Q3 2014 | $302,000 | -71.9% | 23,720 | -50.1% | 0.00% | – |
| Q2 2014 | $1,074,000 | +355.1% | 47,532 | +468.8% | 0.00% | – |
| Q1 2014 | $236,000 | – | 8,356 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 1,355,392 | $29,859,000 | 6.21% |
| Bain Capital Life Sciences Investors, LLC | 3,080,237 | $67,858,000 | 4.26% |
| DAFNA Capital Management LLC | 587,756 | $12,948,000 | 3.85% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 227,388 | $5,009,000 | 2.91% |
| RTW INVESTMENTS, LP | 7,253,857 | $159,802,000 | 2.68% |
| Parkman Healthcare Partners LLC | 331,513 | $7,303,000 | 1.87% |
| Evolutionary Tree Capital Management, LLC | 60,864 | $1,341,000 | 1.02% |
| Eagle Health Investments LP | 69,000 | $1,520,000 | 0.97% |
| Woodline Partners LP | 1,358,796 | $29,934,000 | 0.79% |
| Affinity Asset Advisors, LLC | 40,000 | $881,000 | 0.47% |